12:00 AM
 | 
Oct 10, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Luminate: Completed Phase IIb enrollment

Allegro completed enrollment of 100 patients in the double-blind, placebo-controlled, U.S. Phase IIb PACIFIC trial evaluating 1, 2, 3 and 4 mg intravitreal Luminate given on days 0, 30 and 60. Allegro granted Hanmi...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >